QURE
HEALTHCAREUniqure NV
AI Insight
What's Moving QURE Today?
No stock-specific AI insight has been generated for QURE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.73$71.50
$49.04
Fundamentals
Market Cap$2.8B
P/E Ratio—
EPS$-3.49
Dividend Yield—
Dividend / Share—
ROE-228.2%
Profit Margin—
Debt / Equity—
Trading
Volume3.3M
Avg Volume (10D)—
Shares Outstanding63.1M
QURE News
48 articles- uniQure Announces $150 Million Proposed Public OfferingThe Manila Times·Jun 23, 2026
- QURE Announces Initial Data on Gene therapy for Temporal Lobe EpilepsyYahoo Finance·Jun 22, 2026
- QURE Soars as FDA Backs AMT-130 Data for Accelerated ApprovalYahoo Finance·Jun 19, 2026
- uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe EpilepsyYahoo Finance·Jun 19, 2026
- uniQure Announces Preliminary Data on the First Cohort inGlobeNewswire·Jun 19, 2026
- uniQure’s epilepsy gene therapy showed seizure drops in 3 patientsStock Titan·Jun 19, 2026
- uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework RiskYahoo Finance·Jun 19, 2026
- uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 UpdateYahoo Finance·Jun 19, 2026
- uniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval PathYahoo Finance·Jun 19, 2026
- uniQure Stock Looks Drastically Undervalued After Upbeat FDA MeetingBarchart·Jun 18, 2026
- UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets SaysYahoo Finance·Jun 18, 2026
- UniQure to seek approval of Huntington’s gene therapy after FDA U-turnPharmaceutical-technology·Jun 18, 2026
- SpaceX initiated, Salesforce upgraded: Wall Street's top analyst callsYahoo Finance·Jun 18, 2026
- uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?Yahoo Finance·Jun 18, 2026
- ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?Yahoo Finance·Jun 18, 2026
- UniQure (QURE) Soars 78% on AMT-130 ProgressYahoo Finance·Jun 18, 2026
- Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An EndYahoo Finance·Jun 17, 2026
- UniQure Catapults Nearly 80% On A Gene Therapy Shock From The FDAYahoo Finance·Jun 17, 2026
- Sector Update: Healthcare Stocks Retreat Late AfternoonYahoo Finance·Jun 17, 2026
- This Biotech Stock Is Surging 81% on Surprise Good News From FDAYahoo Finance·Jun 17, 2026
- Stocks Mixed Ahead of FOMC Meeting ResultsBarchart·Jun 17, 2026
- Stocks Supported by Chip Stock Strength and Strong US Retail SalesBarchart·Jun 17, 2026
- UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026Stock Titan·Jun 11, 2026
- uniQure N.V. SEC FilingStock Titan·Jun 11, 2026
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Apr 13, 2026
- INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 10, 2026
- INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 8, 2026
- uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 8, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APEGlobeNewswire Inc.·Apr 7, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QUREGlobeNewswire Inc.·Apr 7, 2026
- ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 6, 2026
- UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QUREGlobeNewswire Inc.·Apr 6, 2026
- INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INOGlobeNewswire Inc.·Apr 6, 2026
- QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” DataGlobeNewswire Inc.·Apr 4, 2026
- UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QUREGlobeNewswire Inc.·Apr 2, 2026
- UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13thGlobeNewswire Inc.·Apr 2, 2026
- uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 1, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QUREGlobeNewswire Inc.·Mar 31, 2026
- Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. InvestorsGlobeNewswire Inc.·Mar 31, 2026
Price Data
Open$44.47
Previous Close$44.39
Day High$49.58
Day Low$44.47
52 Week High$71.50
52 Week Low$8.73
52-Week Range
$8.73$71.50
$49.04
Fundamentals
Market Cap$2.8B
P/E Ratio—
EPS$-3.49
Dividend Yield—
Dividend / Share—
ROE-228.2%
Profit Margin—
Debt / Equity—
Trading
Volume3.3M
Avg Volume (10D)—
Shares Outstanding63.1M
About Uniqure NV
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—